QUEBEC CITY, QUEBEC -- (MARKET WIRE) -- June 30, 2006 -- Advitech inc. (TSX VENTURE: AVI) today announced the following changes in management staff:
- Jean-Luc Martre, Vice-President sales and marketing, will be leaving Advitech on June 30th, 2006. Mr. Beauchesne expressed his thanks for the services Mr. Martre provided throughout the pre-commercialization phase of Dermylex™ and wished him the best of success in his new functions.
- Christian Brouillette MSc, MBA, will become Advitech's sales and marketing director on July 3rd, 2006. He carried out similar functions until recently with a Montreal-based biotechnology company. ''Mr. Brouillette's appointment, given his experience in marketing management, will make it possible to develop the full potential of the different Dermylex™ commercialization agreements and to initiate new partnerships in our target markets,'' commented Renaud Beauchesne, President and Chief Executive Officer of Advitech.
Christian Brouillette has a Bachelor's degree in biochemistry from Universite Laval and a Master's degree in experimental medicine. He also obtained a Master's degree in Business Administration (MBA) in enterprise management. His career has taken him from business development in a company using biotechnology to capture industrial CO2 emissions to sales and marketing in nutraceuticals and biopharmaceuticals, through media placement and financial services.
- Kim Cantin, BSc, becomes Quality Control/Assurance Director. ''Because of our current product launches and the regulatory restrictions of the various markets where we are now working on the implementation phase, quality assurance is a key factor for Advitech and Ms. Cantin's appointment confirms its strategic position in our business plan'', said Renaud Beauchesne. Ms. Cantin has been working for Advitech since February 2005 and will be reporting directly to Mr. Beauchesne.
Ms. Cantin joined Advitech as Coordinator of Clinical and Regulatory Affairs with more than 12 years' experience in the pharmaceutical, cosmetic and nutraceutical industry in charge of clinical and regulatory affairs and QA/QC. Before joining Advitech, Ms. Cantin headed the QA/QC department at Aeterna Laboratories Inc. where she was responsible for the maintenance and improvement of all the quality assurance processes . Ms. Cantin also worked for Omega Laboratories Inc. as supervisor of the microbiology laboratory as well as for Schering Canada Inc. as a microbiologist. She obtained her Bachelor's degree in microbiology and is currently completing the MBA program in pharmaceutical management at Universite Laval.
Advitech is a life science and technology company specializing in the development of clinically tested bioactive ingredients for chronic immune-mediated inflammatory diseases (IMID), such as psoriasis and inflammatory bowel diseases. Advitech's common shares are listed on the TSX Venture Exchange under the symbol AVI. The number of common shares outstanding is 54,799,818.
Dermylex™ is Advitech's orally administered product for mild to moderate plaque psoriasis made from a bioactive ingredient with proven clinical efficacy. On July 5, 2005, the Company reported positive results from its Phase II clinical trial for treating mild to moderate psoriasis. The 112-day, multi-center, double blind, placebo-controlled study, involving 84 patients, confirmed the efficacy and excellent safety profile of Dermylex™ for treating mild to moderate psoriasis. For more information please visit www.dermylex.ca
This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ significantly from those projected herein.